Risk of Depression after 5 Alpha Reductase Inhibitor Medication: Meta-Analysis

다국어 초록 (Multilingual Abstract)

Purpose: Although five-alpha reductase inhibitor (5-ARI) is one of standard treatment for benign prostatic hyperplasia (BPH) or alopecia, potential complications after 5-ARI have been issues recently. This study aimed to investigate the risk of depression after taking 5-ARI and to quantify the risk using meta-analysis.
Materials and Methods: A total of 209,940 patients including 207,798 in 5-ARI treatment groups and 110,118 in control groups from five studies were included for final analysis. Inclusion criteria for finial analysis incudes clinical outcomes regarding depression risk in BPH or alopecia patients. Overall hazard ratio (HR) and odds ratio (OR) for depression were analyzed.
Moderator analysis and sensitivity analysis were performed to determine whether HR or OR could be affected by any variables, including number of patients, age, study type, and control type.
Results: The pooled overall HRs for the 5-ARI medication was 1.23 (95% confidence interval [CI], 0.99–1.54) in a random effects model. The pooled overall ORs for the 5-ARI medication was 1.19 (95% CI, 0.95–1.49) in random effects model. The sub-group analysis showed that non-cohort studies had higher values of HR and OR than cohort studies. Moderator analysis using meta-regression showed that there were no variables that affect the significant difference in HR and OR outcomes.
However, in sensitivity analysis, HR was significantly increased by age (p=0.040).
Conclusions: Overall risk of depression after 5-ARI was significantly not high, however its clinical importance needs validation by further studies. These quantitative results could provide useful information for both clinicians and patients.

참고문헌 (Reference)

1 McVary KT, "Update on AUA guideline on the management of benign prostatic hyperplasia" 185 : 1793-1803, 2011

2 McConnell JD, "The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia" 349 : 2387-2398, 2003

3 Thilers PP, "The association between endogenous free testosterone and cognitive performance : a population-based study in 35 to 90 year-old men and women" 31 : 565-576, 2006

4 Giagulli VA, "Serum testosterone and cognitive function in ageing male : updating the evidence" 10 : 22-30, 2016

5 Hagberg KW, "Risk of incident antidepressant-treated depression associated with use of 5α-reductase inhibitors compared with use of α-blockers in men with benign prostatic hyperplasia : a population-based study using the clinical practice research datalink" 37 : 517-527, 2017

6 U.S. Food and Drug Administration, "Propecia (finasteride)" U.S. Food and Drug Administration

7 McElwee KJ, "Promising therapies for treating and/or preventing androgenic alopecia" 17 : 1-4, 2012

8 Cole MG, "Prognosis of depression in elderly community and primary care populations : a systematic review and meta-analysis" 156 : 1182-1189, 1999

9 Moher D, "Preferred reporting items for systematic reviews and metaanalyses : the PRISMA statement" 8 : 336-341, 2010

10 Tierney JF, "Practical methods for incorporating summary time-to-event data into meta-analysis" 8 : 16-, 2007

11 "Post-Finasteride Syndrome Foundation" Post-Finasteride Syndrome Foundation

12 Ganzer CA, "Persistent sexual, emotional, and cognitive impairment post-finasteride : a survey of men reporting symptoms" 9 : 222-228, 2015

13 Irwig MS, "Persistent sexual side effects of finasteride : could they be permanent?" 9 : 2927-2932, 2012

14 Füllhase C, "New concepts for the treatment of male lower urinary tract symptoms" 25 : 19-26, 2015

15 Unger JM, "Long-term consequences of finasteride vs placebo in the prostate cancer prevention trial" 108 : djw168-, 2016

16 Moinpour CM, "Health-related quality-of-life findings for the prostate cancer prevention trial" 104 : 1373-1385, 2012

17 "Government of Canada. Health product InfoWatch - December 2015" Government of Canada

18 Roehrborn CG, "Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2(dutasteride)in men with benign prostatic hyperplasia" 60 : 434-441, 2002

19 Kruep EJ, "Early symptom improvement and discontinuation of 5-α-reductase inhibitor(5ARI)therapy in patients with benign prostatic hyperplasia(BPH)" 48 : 343-348, 2014

20 Oelke M, "EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction" 64 : 118-140, 2013

21 Pietrzyk B, "Depressive symptoms in patients diagnosed with benign prostatic hyperplasia" 47 : 431-440, 2015

22 Irwig MS, "Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects" 73 : 1220-1223, 2012

23 Nickel JC, "Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia : the Enlarged Prostate International Comparator Study(EPICS)" 108 : 388-394, 2011

24 Handa RJ, "Central 5-alpha reduction of testosterone is required for testosterone’s inhibition of the hypothalamo-pituitary-adrenal axis response to restraint stress in adult male rats" 1529 : 74-82, 2013

25 Welk B, "Association of Suicidality and Depression with 5α-reductase inhibitors" 177 : 683-691, 2017

26 Traish AM, "5α-reductases in human physiology : an unfolding story" 18 : 965-975, 2012